Pediatric Medical Centers Added Arbli to Formularies
The oral suspension eases dosing for young patients, reducing pharmacy compounding needs for hospital staff.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies prioritize developing specialized formulations for patients with difficulty swallowing tablets?
Three U.S. pediatric academic medical centers have added Arbli, an oral losartan suspension, to their formularies to provide flexible dosing for patients at least six years old. The move aims to assist children who struggle with swallowing traditional tablets.
Why it matters
By providing a pre-mixed liquid treatment, the drug eliminates the requirement for extemporaneous pharmacy compounding in pediatric settings. The adoption signals a shift toward specialized delivery formats within the $219 million domestic losartan market.
Scienture Holdings Inc. expanded payer coverage by 12.5 million lives in the second quarter of 2026. This growth occurs within a broader U.S. losartan market that generates $219 million in annual sales across 72 million prescriptions.
The players
Scienture Holdings Inc.
A pharmaceutical developer focused on expanding access to specialized medication formulations.
The details
Arbli provides a 10 mg/mL oral suspension of losartan potassium designed to simplify administration for pediatric patients who cannot swallow conventional tablets. By moving the product into formal hospital formularies, the manufacturer streamlines operational workflows for pharmacy departments that previously relied on manual compounding. The company plans to target further institutional adoption across pediatric settings nationwide.
Timeline
April 2026: The U.S. losartan market generated its reported annual data.
Q2 2026: Scienture expanded payer coverage by 12.5 million lives.
October 2, 2026: Scienture announced the addition of Arbli to three pediatric academic medical centers.
Market Landscape
The transition to pre-mixed oral suspensions reflects an ongoing shift away from the traditional reliance on extemporaneous pharmacy compounding for specialized pediatric dosing. This approach mirrors broader efforts across pharmaceutical manufacturing to reduce labor-intensive hospital pharmacy tasks.
Operators in pediatric healthcare should evaluate how pre-mixed suspensions affect labor hours and inventory costs relative to manual compounding. Review current pharmacy prep-time metrics to determine if commercial alternatives provide sufficient margin gains over existing protocols.
The takeaway
Commercial, pre-mixed formulations are increasingly replacing manual compounding in pediatric hospital settings to improve dosing flexibility and reduce staff time. Managers should monitor future formulary expansions by the company to assess shifts in institutional purchasing trends.
Further reading
For broader trends in pharmaceutical formulary management, see the Healthcare section.
Live Poll
Should pharmaceutical companies prioritize developing specialized formulations for patients with difficulty swallowing tablets?
